By Ransdell Pierson PHILADELPHIA (Reuters) - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals. But the British drugmaker has not thrown in the towel completely and a tiny group of researchers experimenting with new treatments still believe they can find winners. "If we continue to do deals ... ...
via Health News Headlines - Yahoo News http://ift.tt/1pmsGmP
No comments:
Post a Comment